Search

Your search keyword '"Biagio Panascia"' showing total 2 results
Start Over Author "Biagio Panascia"
2 results on '"Biagio Panascia"'

1. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine

Author

Paolo Martelletti, Biagio Panascia, Brigida Fierro, Patrizia Santoro, Carlo Lisotto, Stefano Omboni, Maria Adele Giamberardino, Lidia Savi, D. Moscato, Giorgio Zanchin, Marco Bartolini, Michel D. Ferrari, Filippo Brighina, Grazia Sances, Luigi Alberto Pini, Bartolini, M, Giamberardino, MA, Lisotto, C, Martelletti, P, Moscato, D, Ganascia, B, Savi, L, Pini, LA, Sances, G, Santoro, P, Zanchin, G, Omboni, S, Ferrari, MD, Brighina, F, and Fierro, B

Subjects
Adult, Male, Adolescent, Original, Migraine with Aura, Population, Almotriptan, Carbazoles, Clinical Neurology, Migraine, almotriptan, Frovatriptan, Young Adult, frovatriptan, migraine, patient preference, Double-Blind Method, medicine, Humans, Migraine, Frovatriptan, Almotriptan, Patient preference, Patient preference, education, Aged, education.field_of_study, Cross-Over Studies, business.industry, General Medicine, Middle Aged, medicine.disease, Crossover study, Rizatriptan, Tryptamines, Migraine with aura, Serotonin Receptor Agonists, Treatment Outcome, Anesthesiology and Pain Medicine, Italy, Tolerability, Anesthesia, Acute Disease, Female, Settore MED/26 - Neurologia, Neurology (clinical), medicine.symptom, business, medicine.drug
Abstract

The objective of this study was to evaluate patients’ satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1–3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting

Published
2011

2. Frovatriptan vs almotriptan for treatment of menstrual migraine: a double-blind, randomized, cross-over, multicenter Italian study

Author

Patrizia Santoro, Carlo Lisotto, Filippo Brighina, Brigida Fierro, Biagio Panascia, Ferrari, Marco Bartolini, Giorgio Zanchin, LA Pini, Grazia Sances, Paolo Martelletti, Maria Adele Giamberardino, D. Moscato, Stefano Omboni, and Lidia Savi

Subjects
medicine.medical_specialty, education.field_of_study, Traditional medicine, business.industry, media_common.quotation_subject, Population, Pain relief, Clinical Neurology, Subgroup analysis, General Medicine, medicine.disease, Anesthesiology and Pain Medicine, Migraine, Internal medicine, Almotriptan, Female patient, Poster Presentation, medicine, Neurology (clinical), Frovatriptan, education, business, Menstrual cycle, medicine.drug, media_common
Abstract

Results 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were treated with frovatriptan and 78 with almotriptan. Rate of pain relief at 2and 4-hrs was 36% and 53% for frovatriptan and 41% and 50% for almotriptan (p=NS between treatments). Rate of pain free at 2and 4-hrs was 19% and 47% with frovatriptan and 29% and 54% for almotriptan (p=NS). At 24-hrs, 62% of frovatriptanand 67% of almotriptan-treated patients had pain relief, while 60% vs. 67% were pain free (p=NS). Recurrence at 24-hrs was significantly (p

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results